According to a new study involving treatment for diabetes, help for obesity can become a pill that caused noticeable weight loss for the average participant.
“An anti-obesity medical treatment that involves 10% weight loss in most and 20% in more than a third of participants. This is the beginning of a new era,” said Rachel Batterham, one of the researchers involved in the study and professor of obesity, diabetes and endocrinology and head of the UCL Obesity Research Center and the UCLH Weight Management Center. Twitter
TWTR,
A total of 1,961 adults from North America, South America, Asia and Europe participated in the 68-week trial during 2018 that included the drug semaglutida, an antidiabetic drug used to treat type 2 diabetes. , according to the study published Wednesday in The New England Journal of Medicine,
Individuals received a weekly semaglutide shot on the skin or a placebo, along with counseling sessions to follow a low-calorie diet and increased exercise. Semaglutide is sold under the names Ozempic and Rybelsus by the Danish pharmaceutical company Novo Nordisk NVO,
“Participants who received semaglutida were more likely to lose 5% or more, 10% or more, 15% or more, and 20% or more of initial body weight at week 68 than those who received placebo.” , the study said.
Test participants were 18 years of age or older, with one or more previous dietary attempts to lose weight and a body mass index (BMI) of 30 or higher, or a BMI of 27 with one or more weight, treated or untreated. A normal BMI tends to fall between 18.5 and 24.9.
“Our trial showed that among overweight or obese adults (without diabetes), once-a-week subcutaneous intervention once again lifestyle intervention was associated with substantial, sustained, and moderate weight loss. clinically relevant 14.9%, with 86% of participants achieving at least 5% weight loss, ”the study’s researchers said.
Novo Nordisk has submitted semaglutide as a weight control treatment for regulatory approval to the Food and Drug Administration and the European Medicines Agency.